Helping Melanoma Patients Decide Whether or Not to Choose Adjuvant High-Dose Interferon-α2b

Helping Melanoma Patients Decide Whether or Not to Choose Adjuvant High-Dose Interferon-α2b Karen E. Hurley, Paul B. Chapman Oncologist 2005; 10: 739-742 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in melanoma and cutaneous malignancies and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the benefits of adjuvant high-dose interferon-α therapy to melanoma patients. List the toxicities most commonly associated with adjuvant high-dose interferon-α therapy in melanoma patients. Assist patients with melanoma to decide whether to choose adjuvant high-dose interferon-α therapy. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 25, 2005 Most Recent Review: Oct. 25, 2005* Most Recent Update: Oct. 25, 2005 Date Credit Expires: Oct. 25, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.